NCT03095469 (EODOPWCHD) is a EARLY_PHASE1 clinical trial of Dexmedetomidine in Heart Injuries, sponsored by First Affiliated Hospital Xi'an Jiaotong University.

Who is sponsoring NCT03095469?

NCT03095469 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What drugs are being tested in NCT03095469?

Interventions in NCT03095469: Dexmedetomidine, 0.9%NaCl solution.

What condition does NCT03095469 study?

NCT03095469 studies Heart Injuries.

Is NCT03095469 still recruiting?

NCT03095469 is currently status unknown. Last updated 9 June 2017.

Last reviewed 2017-06-09 · How we verify

NCT03095469: EODOPWCHD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Dexmedetomidine on Patients With Coronary Heart Disease After Percutaneous Coronary Intervention

Status unknown EARLY_PHASE1 Last updated 9 June 2017

What this trial tests

EARLY_PHASE1 trial testing Dexmedetomidine in Heart Injuries in 200 participants. Status unknown.

Timeline

20 August 2017

Primary endpoint
30 November 2017

31 December 2017

Quick facts

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	200
Start date	20 August 2017
Primary completion	30 November 2017
Estimated completion	31 December 2017
Sites	1 location across China

Drugs / interventions tested

Dexmedetomidine (dexmedetomidine) — full drug profile →
0.9%NaCl solution

Conditions studied

Heart Injuries — all drugs for Heart Injuries →

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Who can join

18 and older, any sex, with Heart Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronary heart disease has a high incidence and high death rate. Percutaneous coronary intervention (PCI) is an important method for the treatment of coronary heart disease (CHD). However, PCI may cause myocardial cell injury and myocardial infarction 4 Type(MI4a, Type 4 a myocardial infarction related to PCI). Dexmedetomidine(Dex) is the only anesthetic which has sedative and analgesic effects. Dex currently has been widely used in perioperative management of various surgical.This study intends to verify the effect of heart protection of Dex in perioperative.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Signaling pathways and targeted therapy for myocardial infarction.
Zhang Q, Wang L, Wang S, Cheng H, et al · · 2022 · cited 525× · PMID 35273164 · DOI 10.1038/s41392-022-00925-z

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07306702 — Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients · Phase 4 · withdrawn
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting

Other recruiting trials for Heart Injuries

Currently open trials in the same condition.

NCT06898320 — Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients · recruiting

Other First Affiliated Hospital Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03095469 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
Last refreshed: 9 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03095469.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing